Japan is considering a new approach to its “special” market expansion re-pricing that would exclude drug sales tied to private…
HOME > BUSINESS
BUSINESS
- Lundbeck Japan Plans to Double Workforce by 2028 as It Eyes 3 Drug Approvals
December 2, 2025
- Sawai Eyes Digital and Device Business as Next Growth Pillar after Generics
December 2, 2025
- Mochida Launches Mochi-Gel Cartilage Repair Device, a First for Japan
December 2, 2025
- Shionogi Completes Takeover of JT’s Pharma Business
December 2, 2025
- EMA Starts Review of Padcev-Keytruda for Perioperative Bladder Cancer
December 2, 2025
- Japan’s Prescription Drug Market to Near 12 Trillion Yen in FY2030: IQVIA
December 1, 2025
- Japan Dementia Drug Market to Hit 280 Billion Yen by 2040: Fuji Keizai
December 1, 2025
- JFCR, NEC, Taiho Launch AI-Driven R&D for Cancer Vaccines
December 1, 2025
- Eisai Files Subcutaneous Leqembi Autoinjector in Japan
December 1, 2025
- MSD to End Gardasil Sales in Japan as Use Shifts to 9-Valent HPV Shot
December 1, 2025
- Insmed Japan to Double Sales Force with Brensocatib Launch on the Horizon
November 28, 2025
- Chugai’s Market Cap Tops 14 Trillion Yen, Eyes Further Growth through “Co-Creation”: CEO
November 28, 2025
- Teijin to Receive US$5 Million Milestone as Narcolepsy Drug Enters European PI
November 28, 2025
- Izervay, Vorzzz, Dormicum Syrup Now Available in Japan
November 28, 2025
- Meiji Seeks Label Expansion for Laserphyrin in Cervical Intraepithelial Neoplasia
November 28, 2025
- Jardiance Tops 7 Categories in October Promotion Rankings: Intage
November 28, 2025
- Otsuka’s Sibeprenlimab Earns FDA’s Accelerated Nod for IgAN
November 27, 2025
- Japan PIII Trial Begins for Kagoshima University Spinout’s Oncolytic Virus
November 27, 2025
- Mochida, Ayumi Curb Shipments of Humira Biosimilar 40 mg amid Surging Orders
November 27, 2025
- Toray Out-Licenses Peripheral Neuropathy Drug to Sanodyne
November 27, 2025
ページ
Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
As Japan approaches the Fiscal System Council’s “autumn recommendation,” a notable shift is taking shape. The Ministry of Finance (MOF),…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…